ReviewJournal of lipid research2016
Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.
Review in Journal of lipid research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Dual role of autotaxin as novel biomarker and therapeutic target in pancreatic neuroendocrine neoplasms.Cancer science · 2023Article
- The role of noncoding RNAs in metabolic reprogramming of cancer cells.Cellular & molecular biology letters · 2023Review
- Hypoxia Increases ATX Expression by Histone Crotonylation in a HIF-2α-Dependent Manner.International journal of molecular sciences · 2023Article
- Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis.Cellular and molecular gastroenterology and hepatology · 2022Article
- Emerging roles of platelets in cancer biology and their potential as therapeutic targets.Frontiers in oncology · 2022Review
- Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies.Frontiers in oncology · 2021Review
- Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways.International journal of molecular sciences · 2020Review
- Review
- The FOXM1/ATX signaling contributes to pancreatic cancer development.American journal of translational research · 2020Article
- Autotaxin upregulated by STAT3 activation contributes to invasion in pancreatic neuroendocrine neoplasms.Endocrine connections · 2018Article
- Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.Cancer letters · 2018Article
- Role of autotaxin in cancer stem cells.Cancer metastasis reviews · 2018Review
- Review
- Autotaxin in Pathophysiology and Pulmonary Fibrosis.Frontiers in medicine · 2018Review
- Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity.Journal of lipid research · 2017Article
- Gq/11-Dependent Changes in the Murine Ovarian Transcriptome at the End of Gestation.Biology of reproduction · 2016Article
- Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.Advanced drug delivery reviews · 2016Review
- Introduction to Thematic Review Series: Phospholipases: Central Role in Lipid Signaling and Disease.Journal of lipid research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ectonucleotide pyrophosphatase/phosphodiesterase type 2, more commonly known as autotaxin (ATX), is an ecto-lysophospholipase D encoded by the human ENNP2 gene. ATX is expressed in multiple tissues and participates in numerous key physiologic and pathologic processes, including neural development, obesity, inflammation, and oncogenesis, through the generation of the bioactive lipid, lysophosphatidic acid. Overwhelming evidence indicates that altered ATX activity leads to oncogenesis and cancer progression through the modulation of multiple hallmarks of cancer pathobiology. Here, we review the structural and catalytic characteristics of the ectoenzyme, how its expression and maturation processes are regulated, and how the systemic integration of its pleomorphic effects on cells and tissues may contribute to cancer initiation, progression, and therapy. Additionally, the up-to-date spectrum of the most frequent ATX genomic alterations from The Cancer Genome Atlas project is reported for a subset of cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.